Freeline Therapeutics (NASDAQ:FRLN) Now Covered by Analysts at Guggenheim

Analysts at Guggenheim started coverage on shares of Freeline Therapeutics (NASDAQ:FRLN) in a report issued on Wednesday, Benzinga reports. The firm set a “buy” rating and a $17.00 price target on the stock. Guggenheim’s price objective indicates a potential upside of 94.51% from the company’s previous close.

A number of other equities analysts have also recently issued reports on FRLN. Stifel Nicolaus started coverage on Freeline Therapeutics in a report on Monday, March 8th. They issued a “buy” rating and a $21.00 target price on the stock. Zacks Investment Research lowered Freeline Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 17th. Mizuho assumed coverage on Freeline Therapeutics in a research note on Monday, March 29th. They set a “buy” rating and a $27.00 price target for the company. Finally, Morgan Stanley cut their price objective on shares of Freeline Therapeutics from $28.00 to $22.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.14.

NASDAQ:FRLN opened at $8.74 on Wednesday. Freeline Therapeutics has a 52-week low of $8.31 and a 52-week high of $21.69. The business’s 50-day moving average price is $12.35 and its 200 day moving average price is $15.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of FRLN. CHI Advisors LLC boosted its holdings in shares of Freeline Therapeutics by 2.8% in the fourth quarter. CHI Advisors LLC now owns 1,361,064 shares of the company’s stock valued at $24,853,000 after buying an additional 36,700 shares during the period. Polygon Management Ltd. grew its holdings in shares of Freeline Therapeutics by 2.7% during the fourth quarter. Polygon Management Ltd. now owns 750,000 shares of the company’s stock worth $13,695,000 after buying an additional 20,000 shares in the last quarter. Finally, Morgan Stanley acquired a new stake in Freeline Therapeutics in the 3rd quarter valued at approximately $206,000. 38.48% of the stock is owned by institutional investors and hedge funds.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B.

Further Reading: What Is Dividend Yield and How Do You Calculate It?

Analyst Recommendations for Freeline Therapeutics (NASDAQ:FRLN)

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.